{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:20:15Z","timestamp":1779250815916,"version":"3.51.4"},"reference-count":56,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","semarthritisrheumatism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.semarthrit.2016.12.003","type":"journal-article","created":{"date-parts":[[2016,12,10]],"date-time":"2016-12-10T01:48:05Z","timestamp":1481334485000},"page":"767-774","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Evidence-based management of systemic sclerosis: Navigating recommendations and guidelines"],"prefix":"10.1016","volume":"46","author":[{"given":"Russell Edward","family":"Pellar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet Elizabeth","family":"Pope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2016.12.003_bib1","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3389\/fimmu.2015.00272","article-title":"Pathogenesis of systemic sclerosis","volume":"6","author":"Pattanaik","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/MD.0b013e3181dde28d","article-title":"(CSRG). Systemic sclerosis: establishing diagnostic criteria","volume":"89","author":"Hudson","year":"2010","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib3","first-page":"1867","article-title":"Increased prevalence of scleroderma in Southwestern Ontario : a cluster analysis","volume":"29","author":"Thompson","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib4","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jbspin.2008.07.003","article-title":"Systemic sclerosis: an update in 2008","volume":"75","author":"Allanore","year":"2008","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib5","first-page":"1117","article-title":"Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases","volume":"33","author":"Johnson","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib6","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/art.11073","article-title":"Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population","volume":"48","author":"Mayes","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib7","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European league against rheumatism collaborative initiative","volume":"65","author":"Van Den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-1-4419-5774-0_4","author":"Barnes","year":"2012","journal-title":"Scleroderma: From Pathogenesis to Comprehensive Management, Chapter 4: Epidemiology and Environmental Risk Factors"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib9","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"Leroy","year":"1988","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib10","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/art.21714","article-title":"Scleroderma treatment differs between experts and general rheumatologists","volume":"55","author":"Pope","year":"2006","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib11","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.096677","article-title":"EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)","volume":"68","author":"Kowal-Bielecka","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","author":"Kowal-Bielecka","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib13","article-title":"BSR and BHPR guideline for the management of systemic sclerosis\u2014executive summary. BSR and BHPR Standards, Guidelines and Audit Working Group","author":"Denton","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib14","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/1529-0131(200108)44:8<1841::AID-ART322>3.0.CO;2-8","article-title":"Calcium-channel blockers for Raynaud\u2032s phenomenon in systemic sclerosis","volume":"44","author":"Thompson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib15","first-page":"CD000953","article-title":"Iloprost and cisaprost for Raynaud\u2032s phenomenon in progressive systemic sclerosis","author":"Pope","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib16","first-page":"1407","article-title":"Intravenous iloprost treatment of Raynaud\u05f3s phenomenon and ischemic ulcers secondary to systemic sclerosis","volume":"19","author":"Wigley","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib17","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/0003-4819-120-3-199402010-00004","article-title":"Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study","volume":"120","author":"Wigley","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib18","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/art.20676","article-title":"Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist","volume":"50","author":"Korn","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"Suppl. II","key":"10.1016\/j.semarthrit.2016.12.003_bib19","first-page":"S90","article-title":"Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis","volume":"65","author":"Seibold","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/(SICI)1096-9926(199901)59:1<51::AID-TERA10>3.0.CO;2-I","article-title":"Developmental toxicity and toxicokinetics of two endothelin receptor antagonists in rats and rabbits","volume":"59","author":"Treinen","year":"1999","journal-title":"Teratology"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib21","doi-asserted-by":"crossref","first-page":"113","DOI":"10.5414\/CPP44113","article-title":"Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol","volume":"44","author":"van Giersbergen","year":"2006","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib22","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib23","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib24","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Galie","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib25","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib26","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/978-3-662-45805-1_12","article-title":"Soluble guanylate cyclase stimulators in pulmonary hypertension","volume":"2018","author":"Stasch","year":"2013","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib27","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/rheumatology\/35.4.364","article-title":"Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial","volume":"35","author":"van den Hoogen","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib28","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","article-title":"A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma","volume":"44","author":"Pope","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib29","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib30","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib31","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1164\/ajrccm.155.2.9032171","article-title":"Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders","volume":"155","author":"Lynch","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib32","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJM197906213002505","article-title":"Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting enzyme blockade","volume":"300","author":"Lopez-Ovejero","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib33","doi-asserted-by":"crossref","first-page":"352","DOI":"10.7326\/0003-4819-113-5-352","article-title":"Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors","volume":"113","author":"Steen","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib34","doi-asserted-by":"crossref","first-page":"600","DOI":"10.7326\/0003-4819-133-8-200010170-00010","article-title":"Long-term outcomes of scleroderma renal crisis","volume":"133","author":"Steen","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib35","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/anr.1780320911","article-title":"Normotensive renal failure in systemic sclerosis","volume":"32","author":"Helfrich","year":"1989","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib36","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1002\/art.10589","article-title":"Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial","volume":"46","author":"DeMarco","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib37","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O","article-title":"Case\u2013control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis","volume":"41","author":"Steen","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"Suppl.","key":"10.1016\/j.semarthrit.2016.12.003_bib38","first-page":"S743","article-title":"Scleroderma renal crisis: presentation, outcome and risk factors based on a retrospective multicenter study of 50 patients","volume":"54","author":"Teixeira","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib39","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1053\/gast.1997.v112.pm9178669","article-title":"Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis","volume":"112","author":"Chiba","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib40","first-page":"CD002095","article-title":"Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease","volume":"3","author":"van Pinxteren","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib41","first-page":"550","article-title":"Effect of erythromycin on gastric and gallbladder emptying and gastrointestinal symptoms in scleroderma patients is maintained medium term","volume":"89","author":"Fiorucci","year":"1994","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib42","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1007\/BF02208652","article-title":"Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction","volume":"40","author":"Verne","year":"1995","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib43","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1056\/NEJM199111213252102","article-title":"Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma","volume":"325","author":"Soudah","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib44","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000103892","article-title":"Small intestinal bacterial overgrowth: diagnosis and treatment","volume":"25","author":"Gasbarrini","year":"2007","journal-title":"Dig Dis"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib45","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/nrrheum.2009.98","article-title":"Connective tissue diseases: new evidence-based guidelines for treating SSc","volume":"5","author":"Pope","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib46","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib47","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/BOR.0b013e3282e6f534","article-title":"Adult stem cell treatment of scleroderma","volume":"19","author":"Tyndall","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib48","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/acr.22018","article-title":"Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis","volume":"65","author":"Tingey","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib49","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/rheumatology\/keq310","article-title":"Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey","volume":"50","author":"Bassel","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib50","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3899\/jrheum.080281","article-title":"Quality of life in patients with systemic sclerosis compared to the general population and patients with other chronic conditions","volume":"36","author":"Hudson","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib51","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.semarthrit.2012.01.003","article-title":"Treatment of systemic sclerosis complications: what to use when first-line treatment fails-a consensus of systemic sclerosis experts","volume":"42","author":"Walker","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib52","article-title":"A comparison between general rheumatologists and scleroderma experts with respect to following systemic sclerosis guidelines","author":"Reed","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib53","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3899\/jrheum.101262","article-title":"Expert agreement on EULAR\/EUSTAR recommendations for the management of systemic sclerosis","volume":"38","author":"Walker","year":"2011","journal-title":"J Rheum"},{"issue":"2 Suppl. 71","key":"10.1016\/j.semarthrit.2016.12.003_bib54","first-page":"S38","article-title":"Best practices in scleroderma: an analysis of practice variability in SSc centres within the Canadian Scleroderma Research Group (CSRG)","volume":"30","author":"Harding","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib55","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3899\/jrheum.110121","article-title":"Agreement with guidelines from a large database for management of systemic sclerosis: results from the Canadian Scleroderma Research Group","volume":"39","author":"Pope","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2016.12.003_bib56","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1093\/rheumatology\/kes079","article-title":"Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: Results from the CATCH cohort","volume":"51","author":"McKeown","year":"2012","journal-title":"Rheumatology (Oxford)"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017216304644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017216304644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T21:33:27Z","timestamp":1601242407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017216304644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0049017216304644"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2016.12.003","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence-based management of systemic sclerosis: Navigating recommendations and guidelines","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2016.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}